A Phase II Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 25 Jan 2017 Planned End Date changed from 1 Jul 2015 to 1 Jan 2018.
- 09 Aug 2016 Status changed from recruiting to active, no longer recruiting.